logo
ResearchBunny Logo
Abstract
This phase 3 PARADIGM trial (n=733) investigated the association between circulating tumor DNA (ctDNA) gene alterations and efficacy outcomes in patients with RAS wild-type metastatic colorectal cancer (mCRC) treated with first-line panitumumab plus modified FOLFOX6 or bevacizumab plus modified FOLFOX6. Overall survival was longer with panitumumab in patients with ctDNA lacking gene alterations (negative hyperselected), but similar or inferior in those with any ctDNA alteration, regardless of tumor sidedness. Negative hyperselection using ctDNA may guide optimal treatment selection.
Publisher
Nature Medicine
Published On
Mar 01, 2024
Authors
Kohei Shitara, Kei Muro, Jun Watanabe, Kentaro Yamazaki, Hisatsugu Ohori, Manabu Shiozawa, Atsuo Takashima, Mitsuru Yokota, Akitaka Makiyama, Naoya Akazawa, Hitoshi Ojima, Yasuhiro Yuasa, Keisuke Miwa, Hirofumi Yasui, Eiji Oki, Takeo Sato, Takeshi Naitoh, Yoshito Komatsu, Takeshi Kato, Ikuo Mori, Kazunori Yamanaka, Masamitsu Hihara, Junpei Soeda, Toshihiro Misumi, Kouji Yamamoto, Riu Yamashita, Kiwamu Akagi, Atsushi Ochiai, Hiroyuki Uetake, Katsuya Tsuchihara, Takayuki Yoshino
Tags
circulating tumor DNA
colorectal cancer
panitumumab
first-line treatment
overall survival
ctDNA alterations
metastatic cancer
Listen, Learn & Level Up
Over 10,000 hours of research content in 25+ fields, available in 12+ languages.
No more digging through PDFs—just hit play and absorb the world's latest research in your language, on your time.
listen to research audio papers with researchbunny